 IRVINE, CA ACCESSWIRE September 7, 2021 Hancock Jaffe Laboratories, Inc. NASDAQ:HJLI, a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a leading life sciences investment firm, to purchase 20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq rules. The offering consists of 2,540,650 shares of common stock and pre-funded warrants at a purchase price of 7.8720 per share. 